Abvc Biopharma (ABVC) FCF Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly FCF Margin came in at 76.89% in Q4 2025, up 3579073.0% YoY from N/an in Q4 2024, and up 100.22% on a QoQ basis from 35713.84% in Q4 2024.
Abvc Biopharma (ABVC) FCF Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of FCF Margin data on file, last reported at 76.89% in Q4 2025.
- Quarterly FCF Margin rose 3579073.0% year-over-year to 76.89% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1167.49% (up 152251.0% YoY) and the FY2025 annual result came in at 9397.08%, down 904206.0% from the prior year.
- FCF Margin climbed to 76.89% in Q4 2025, from 35713.84% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 641.43% in Q4 2021 to a low of 79320.83% in Q1 2024.
- A 5-year average of 10469.64% and a median of 1225.63% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin sank 7815329 bps — and 2025, when it soared 3579073 bps.
- Tracing ABVC's FCF Margin over 5 years: stood at 641.43% in 2021, then sank by 112 bps to 78.3% in 2022, then tumbled by 25294 bps to 19882.82% in 2023, then sank by 80 bps to 35713.84% in 2024, then surged by 100 bps to 76.89% in 2025.
- The last three FCF Margin figures came in at 76.89% (Q4 2025), 35713.84% (Q4 2024), and 15.47% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 76.89% |
| Dec 31, 2024 | -35,713.84% |
| Sep 30, 2024 | 15.47% |
| Jun 30, 2024 | -180.49% |
| Mar 31, 2024 | -79,320.83% |
| Dec 31, 2023 | -19,882.82% |
| Sep 30, 2023 | -5,915.08% |
| Jun 30, 2023 | -14,729.53% |
| Mar 31, 2023 | -1,167.54% |
| Dec 31, 2022 | -78.30% |
| Sep 30, 2022 | -1,225.63% |
| Jun 30, 2022 | -1,103.17% |
| Mar 31, 2022 | -12,032.26% |
| Dec 31, 2021 | 641.43% |
| Sep 30, 2021 | -2,238.43% |
| Jun 30, 2021 | -4,592.74% |
| Mar 31, 2021 | -536.98% |
| Dec 31, 2020 | -3,518.15% |
| Sep 30, 2020 | -284.55% |
| Jun 30, 2020 | -625.19% |